Skip to main
CLYM

CLYM Stock Forecast & Price Target

CLYM Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Climb Bio Inc is positioned for significant growth due to its unique product candidate, budoprutug, which addresses a competitive gap in the treatment of immune-mediated diseases, expecting peak sales of $1.8 billion from a revised estimate of 15.5k patients. The company's strategic acquisition of Tenet Medicines and a $120 million private investment in public equity (PIPE) have bolstered its valuation, reflecting investor confidence in its pipeline. Positive clinical data from both budoprutug and CLYM116 suggests strong potential for efficacy and remission rates, promising a similar trajectory for equity appreciation as seen in comparable biotech firms.

Bears say

Climb Bio Inc has consistently reported losses and has never achieved profitability, raising significant concerns about its financial sustainability. The company faces substantial risks related to the advancement of its clinical candidates, budoprutug and CYLM116, as negative clinical data or failure to secure regulatory approvals could adversely impact its future prospects. Additionally, potential dilution risks and uncertainties related to partnerships further cloud the outlook for Climb Bio’s stock, indicating that the company's financial stability may be at jeopardy.

CLYM has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Climb Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Climb Bio Inc (CLYM) Forecast

Analysts have given CLYM a Buy based on their latest research and market trends.

According to 4 analysts, CLYM has a Buy consensus rating as of Jan 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Climb Bio Inc (CLYM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.